- Conditions
- Arginase I Deficiency, Hyperargininemia
- Interventions
- Pegzilarginase, Placebo
- Drug
- Lead sponsor
- Immedica Pharma AB
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 17
- States / cities
- Rogers, Arkansas • Orange, California • Stanford, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arginase I Deficiency, Hyperargininemia
- Interventions
- AEB1102
- Drug
- Lead sponsor
- Aeglea Biotherapeutics
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Stanford, California • Gainesville, Florida • Detroit, Michigan + 3 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Co-ArgI-PEG modified human arginase I
- Drug
- Lead sponsor
- Immedica Pharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 7
- States / cities
- Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
- Conditions
- Advanced Cancers
- Interventions
- Co-ArgI-PEG
- Drug
- Lead sponsor
- Immedica Pharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
- Interventions
- Pegtarviliase IV, Pegtarviliase SC
- Drug
- Lead sponsor
- Aeglea Biotherapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Arginase I Deficiency, Hyperargininemia
- Interventions
- AEB1102
- Drug
- Lead sponsor
- Immedica Pharma AB
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- Stanford, California • Gainsville, Florida • New York, New York + 1 more
- Conditions
- Small-cell Lung Cancer
- Interventions
- Pegzilarginase, Pembrolizumab
- Drug
- Lead sponsor
- Aeglea Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Aurora, Colorado • Denver, Colorado + 18 more